MA31314B1 - Derives de pleuromutiline pour le traitement de maladies transmises par des microbes - Google Patents

Derives de pleuromutiline pour le traitement de maladies transmises par des microbes

Info

Publication number
MA31314B1
MA31314B1 MA32283A MA32283A MA31314B1 MA 31314 B1 MA31314 B1 MA 31314B1 MA 32283 A MA32283 A MA 32283A MA 32283 A MA32283 A MA 32283A MA 31314 B1 MA31314 B1 MA 31314B1
Authority
MA
Morocco
Prior art keywords
alkyl
microbes
treatment
cycloalkyl
diseases transmitted
Prior art date
Application number
MA32283A
Other languages
Arabic (ar)
English (en)
Inventor
Rosemarie Mang
Werner Heilmayer
Rudolf Badegruber
Dirk Strickmann
Rodger Novak
Mathias Ferencic
Atchyuta Rama Chandra Murty Bulusu
Original Assignee
Nabriva Therapeutics Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38668870&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA31314(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nabriva Therapeutics Ag filed Critical Nabriva Therapeutics Ag
Publication of MA31314B1 publication Critical patent/MA31314B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/52—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/61—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/72—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 spiro-condensed with carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/93—Spiro compounds
    • C07C2603/95—Spiro compounds containing "not free" spiro atoms
    • C07C2603/98—Spiro compounds containing "not free" spiro atoms containing at least one ring with more than six ring members
    • C07C2603/99—Spiro compounds containing "not free" spiro atoms containing at least one ring with more than six ring members containing eight-membered rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention porte sur un composé de formule (i), dans laquelle n vaut 0 à 4; m vaut 0 ou 1, à la condition que l'atome de soufre et r3 soient en position voisine (si m = 0, r3 est en position 2', et si m = 1, r3 est en position 1'); r représente éthyle ou vinyle; r1 représente hydrogène ou alkyle en c1-6; r2 représente hydrogène ou cycloalkyle en c3-6 ou alkyle en c1-6 non substitué ou alkyle en c1-6 substitué par un ou plusieurs hydroxy; de préférence un ou deux méthoxy, halogène, cycloalkyle en c3-6, ou r1 et r2, conjointement avec l'atome d'azote auquel ils sont attachés, forment un noyau hétérocyclique de 5 à 7 chaînons contenant au moins 1 atome d'azote ou 1 azote et 1 hétéroatome supplémentaire, par exemple, choisi parmi n ou o, ou r1 représente hydroxy et r2 représente formyle; r3 représente oh, or4, un atome d'halogène, ou à la condition que r3 soit lié en 2', r3 représente -o-(ch2)p-o-, avec p valant 2 ou 3; r4 représente alkyle en c1-6 non substitué ou cycloalkyle en c3-6.
MA32283A 2007-03-20 2009-10-15 Derives de pleuromutiline pour le traitement de maladies transmises par des microbes MA31314B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07450053A EP1972618A1 (fr) 2007-03-20 2007-03-20 Dérivés de pleuromutilin pour le traitement des maladies médiées par des microbes
PCT/AT2008/000097 WO2008113089A1 (fr) 2007-03-20 2008-03-19 Dérivés de pleuromutiline pour le traitement de maladies transmises par des microbes

Publications (1)

Publication Number Publication Date
MA31314B1 true MA31314B1 (fr) 2010-04-01

Family

ID=38668870

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32283A MA31314B1 (fr) 2007-03-20 2009-10-15 Derives de pleuromutiline pour le traitement de maladies transmises par des microbes

Country Status (32)

Country Link
US (12) US20090118366A1 (fr)
EP (3) EP1972618A1 (fr)
JP (2) JP5479114B2 (fr)
KR (1) KR101478593B1 (fr)
CN (2) CN104211624B (fr)
AT (1) ATE523486T1 (fr)
AU (1) AU2008229609B2 (fr)
BR (1) BRPI0809023B8 (fr)
CA (1) CA2678795C (fr)
CY (2) CY1117482T1 (fr)
DK (2) DK2380874T3 (fr)
EA (1) EA018707B1 (fr)
ES (2) ES2375503T3 (fr)
FI (1) FIC20200038I1 (fr)
HK (1) HK1140185A1 (fr)
HR (1) HRP20110869T1 (fr)
HU (1) HUS2100001I1 (fr)
IL (1) IL200440A (fr)
LT (1) LTPA2020531I1 (fr)
MA (1) MA31314B1 (fr)
MY (1) MY148916A (fr)
NL (1) NL301086I2 (fr)
NO (1) NO2021002I1 (fr)
NZ (1) NZ579011A (fr)
PL (1) PL2137143T3 (fr)
PT (2) PT2380874T (fr)
SI (1) SI2137143T1 (fr)
TN (1) TN2009000347A1 (fr)
TW (1) TWI406657B (fr)
UA (1) UA97836C2 (fr)
WO (1) WO2008113089A1 (fr)
ZA (1) ZA200905590B (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1808431A1 (fr) * 2006-01-16 2007-07-18 Nabriva Therapeutics Forschungs GmbH Dérivés de mutiline et leur utilisation en tant que composé pharmaceutique
EP1972618A1 (fr) 2007-03-20 2008-09-24 Nabriva Therapeutics AG Dérivés de pleuromutilin pour le traitement des maladies médiées par des microbes
EP2159220A1 (fr) * 2008-09-02 2010-03-03 Nabriva Therapeutics AG Composés organiques
WO2010056855A1 (fr) * 2008-11-13 2010-05-20 Teva Pharmaceutical Industries Ltd. Préparation de rétapamuline par l'intermédiaire de son précurseur pleuromutiline-thiol
EP2399904A1 (fr) * 2010-05-26 2011-12-28 Nabriva Therapeutics AG Procédé de préparation de pleuromutilines
EP2390245A1 (fr) * 2010-05-26 2011-11-30 Nabriva Therapeutics AG Amines énantiomériquement pures
EP2433926A1 (fr) 2010-09-09 2012-03-28 Nabriva Therapeutics AG Dérivés de pleuromutilin pour le traitement des maladies médiées par des microbes
EP2731933B1 (fr) 2011-07-15 2015-09-30 Bayer Intellectual Property GmbH Dérivés de 2,3-diphényl-valéronitrile, leurs procédés de préparation et leur utilisation comme herbicides et régulateurs de croissance de plantes
CN103265487A (zh) * 2013-06-05 2013-08-28 北京理工大学 截短侧耳素扩环衍生物及其制备方法和用途
CN104803911B (zh) * 2014-01-23 2018-01-05 中国科学院上海药物研究所 一类截短侧耳素化合物、其药物组合物、合成方法与用途
ES2553929B1 (es) * 2014-06-11 2016-09-26 Antonio Javier MORENO CASTRO Dispositivo de modificación/destrucción selectiva de tejidos orgánicos
WO2016202788A1 (fr) * 2015-06-17 2016-12-22 Nabriva Therapeutics Ag Formulations pharmaceutiques injectables de léfamuline
GEP20217243B (en) 2015-06-18 2021-04-26 Sprl Estetra Orodispersible dosage unit containing an estetrol component
NO3106148T3 (fr) 2015-06-18 2018-08-11
TWI762573B (zh) 2017-02-10 2022-05-01 奧地利商納畢瓦治療有限責任公司 截短側耳素之純化
JOP20200260A1 (ar) 2018-04-19 2019-10-19 Estetra Sprl مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
CN111170911A (zh) * 2019-09-29 2020-05-19 安帝康（无锡）生物科技有限公司 用于治疗细菌感染性疾病的截短侧耳素类化合物
CN111170893B (zh) * 2020-01-19 2022-04-26 郑州依米花手性药物研究有限公司 Lefamulin的中间体化合物及其在Lefamulin制备中的应用
WO2021209596A1 (fr) 2020-04-17 2021-10-21 Nabriva Therapeutics GmbH Utilisation thérapeutique de pleuromutilines
CN115397407A (zh) * 2020-04-17 2022-11-25 纳布里瓦治疗有限责任公司 截短侧耳素类化合物的新治疗用途
BR112022020007A2 (pt) * 2020-04-17 2022-11-22 Nabriva Therapeutics GmbH Uso terapêutico de pleuromutilinas
WO2023152115A1 (fr) 2022-02-09 2023-08-17 Nabriva Therapeutics GmbH Léfamuline et ses dérivés pour utilisation dans le traitement contre une bactérie en forme de spirale
EP4338732A1 (fr) 2022-09-16 2024-03-20 Nabriva Therapeutics GMBH Lefamulin et ses dérivés pour leur utilisation dans le traitement de la tularémie

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4130709A (en) * 1977-12-08 1978-12-19 Eli Lilly And Company Pleuromutilin glycoside derivatives
DE4023848C2 (de) 1990-07-27 1994-04-21 Huels Chemische Werke Ag Verfahren zur Herstellung von 3-C¶1¶- bis C¶6¶-Alkoxycarbonylcyclohexanpropionsäureestern
GB9918037D0 (en) * 1999-07-30 1999-09-29 Biochemie Gmbh Organic compounds
GB0017031D0 (en) * 2000-07-11 2000-08-30 Biochemie Gmbh Antimicrobials
GB0207495D0 (en) 2002-03-28 2002-05-08 Biochemie Gmbh Organic compounds
GB0209262D0 (en) 2002-04-23 2002-06-05 Biochemie Gmbh Organic compounds
MXPA05000984A (es) * 2002-07-24 2005-09-12 Sandoz Ag Derivados de pleuromutilina como antimicrobianos.
GB0513058D0 (en) * 2005-06-27 2005-08-03 Sandoz Ag Organic compounds
EP1896404B1 (fr) * 2005-06-27 2014-09-17 Nabriva Therapeutics AG Derives de la pleuromutiline contenant un groupe hydroxyamino- ou acyloxyaminocycloalkyle
GB0515995D0 (en) * 2005-08-03 2005-09-07 Sandoz Ag Organic compounds
EP1972618A1 (fr) 2007-03-20 2008-09-24 Nabriva Therapeutics AG Dérivés de pleuromutilin pour le traitement des maladies médiées par des microbes

Also Published As

Publication number Publication date
NL301086I2 (nl) 2021-01-28
TN2009000347A1 (fr) 2010-12-31
US8153689B2 (en) 2012-04-10
EP2380874A2 (fr) 2011-10-26
CY2020032I2 (el) 2020-11-25
CN104211624A (zh) 2014-12-17
US20090118366A1 (en) 2009-05-07
CN101668738B (zh) 2014-10-15
MY148916A (en) 2013-06-14
JP5479114B2 (ja) 2014-04-23
BRPI0809023A2 (pt) 2014-09-23
DK2380874T3 (en) 2017-03-27
LTPA2020531I1 (lt) 2020-11-10
US20220218713A1 (en) 2022-07-14
ES2375503T3 (es) 2012-03-01
KR20090123882A (ko) 2009-12-02
IL200440A0 (en) 2010-04-29
KR101478593B1 (ko) 2015-01-02
US20120029072A1 (en) 2012-02-02
IL200440A (en) 2013-09-30
EP2380874A3 (fr) 2011-12-07
ZA200905590B (en) 2010-10-27
HUS2100001I1 (hu) 2021-03-01
US8071643B2 (en) 2011-12-06
CA2678795C (fr) 2014-11-18
US20180303842A1 (en) 2018-10-25
US20140256731A1 (en) 2014-09-11
PT2137143E (pt) 2011-12-22
TWI406657B (zh) 2013-09-01
AU2008229609A1 (en) 2008-09-25
PL2137143T3 (pl) 2012-02-29
JP2014159416A (ja) 2014-09-04
CN104211624B (zh) 2017-12-15
BRPI0809023B8 (pt) 2021-05-25
EP2137143A1 (fr) 2009-12-30
JP2010522143A (ja) 2010-07-01
CY1117482T1 (el) 2017-04-26
BRPI0809023B1 (pt) 2020-12-01
US20200030335A1 (en) 2020-01-30
CA2678795A1 (fr) 2008-09-25
US20200281933A1 (en) 2020-09-10
AU2008229609B2 (en) 2012-03-29
FIC20200038I1 (fi) 2020-10-01
EA018707B1 (ru) 2013-10-30
ES2620459T3 (es) 2017-06-28
EA200970868A1 (ru) 2010-02-26
WO2008113089A1 (fr) 2008-09-25
US20100035987A1 (en) 2010-02-11
CN101668738A (zh) 2010-03-10
US20190175603A1 (en) 2019-06-13
HK1140185A1 (en) 2010-10-08
UA97836C2 (ru) 2012-03-26
TW200904402A (en) 2009-02-01
EP2137143B1 (fr) 2011-09-07
SI2137143T1 (sl) 2012-01-31
CY2020032I1 (el) 2020-11-25
DK2137143T3 (da) 2012-01-02
PT2380874T (pt) 2017-04-03
EP2380874B1 (fr) 2016-12-28
US20130040954A1 (en) 2013-02-14
ATE523486T1 (de) 2011-09-15
NZ579011A (en) 2011-03-31
US20210113571A1 (en) 2021-04-22
NO2021002I1 (no) 2021-01-15
HRP20110869T1 (hr) 2011-12-31
US20170266194A1 (en) 2017-09-21
JP5893651B2 (ja) 2016-03-23
EP1972618A1 (fr) 2008-09-24

Similar Documents

Publication Publication Date Title
MA31314B1 (fr) Derives de pleuromutiline pour le traitement de maladies transmises par des microbes
MA32456B1 (fr) Dérivé hétérocyclique contenant du soufre ayant une activité inhibant la b-sécrétase
TW200616961A (en) Carbostyril compound
MA31906B1 (fr) Inhibiteurs de la replication du virus de limmunodeficience humaine
BRPI0513433A (pt) derivados de hidantoìna para o tratamento de distúrbios inflamatórios
HK1139381A1 (en) Bicyclic -amino acid derivative
MA31710B1 (fr) (carboxylalkylenephenyl)phényloxamides, procédés pour la production de ceux-ci et utilisation de ceux-ci en tant que medicament
CY1107956T1 (el) Χρηση υποκατεστημενων 2-αμινοτετραλινιων για την προληπτικη αντιμετωπιση της νοσου του παρκινσον
EA200601830A1 (ru) Ортозамещённые арильные или гетероарильные амидные соединения
MA27725A1 (fr) Benzopyrannes utiles pour le traitement d'etats inflammatoires
MXPA06011194A (es) Tiadiazolidinonas como inhibidores de gsk-3.
NO20082719L (no) Aryl-isoksazol-4-yl-oksadiazolderivater
WO2007057790A3 (fr) Dérivés de pyrimidone bicycliques substitués
MA34361B1 (fr) Dérivés de tétrahydro-pyrido-pyrimidine
TW200619212A (en) Morpholine derivatives
ATE528289T1 (de) 1,2-disubstituierte 4- benzylaminopyrrolidinderivate als für die behandlung von krankheiten wie hyperlipidämie oder arteriosklerose geeignete cetp-inhibitoren
MA33128B1 (fr) Derives de triazolopyridine utilises comme inhibiteurs de la p38 map kinase
MA33618B1 (fr) Agent thérapeutique destiné aux troubles de l'humeur
EA200501311A1 (ru) ПРОИЗВОДНЫЕ ЗАМЕЩЁННОГО 8-ПЕРФТОРАЛКИЛ-6,7,8,9-ТЕТРАГИДРОПИРИМИДО[1,2-a]ПИРИМИДИН-4-ОНА
DE502005008351D1 (de) Chinolinderivat, dessen verwendung, herstellung und dieses enthaltendes arzneimittel
DE602006014022D1 (de) 5-substituierte indol-2-carbonsäureamidderivate
EA200700707A1 (ru) Производные 2-ациламинотиазола
EA200970555A1 (ru) Трициклическое соединение и его медицинское применение
EA200970642A1 (ru) Трициклическое соединение и его фармацевтическое применение
WO2009008345A1 (fr) Composé complexe métallique, composition thérapeutique contre le cancer comprenant le composé complexe métallique comme principe actif et intermédiaire pour la production du composé complexe métallique